Last reviewed · How we verify
pantoprazole bolus
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Acute gastric acid suppression in hospitalized patients, Peptic ulcer disease, Gastroesophageal reflux disease (GERD).
At a glance
| Generic name | pantoprazole bolus |
|---|---|
| Sponsor | Kwong Wah Hospital |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Pantoprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This reduces intragastric pH and acid-related damage to the gastrointestinal mucosa. The bolus formulation provides rapid intravenous delivery for acute acid suppression in clinical settings.
Approved indications
- Acute gastric acid suppression in hospitalized patients
- Peptic ulcer disease
- Gastroesophageal reflux disease (GERD)
- Stress ulcer prophylaxis
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Hypomagnesemia (with chronic use)
Key clinical trials
- Role of Octreotide in Non Variceal Bleeding (PHASE2, PHASE3)
- Efficacy of Low Dose Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding (NA)
- Vasoactive Drugs in Real World Practice (PHASE4)
- Core Temperature Variations During Midazolam vs Propofol Sedation for Neuraxial Anesthesia (NA)
- Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding (PHASE4)
- High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment (NA)
- Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pantoprazole bolus CI brief — competitive landscape report
- pantoprazole bolus updates RSS · CI watch RSS
- Kwong Wah Hospital portfolio CI